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Abstract 
Complex three-dimensional structure of therapeutic proteins and their tendency for 
aggregate formation, is a challenge for biopharmaceutical companies, since such aggregates 
can evoke an immune response upon administration, cause blood vessel occlusion and lead 
to loss of effective monomeric proteins. Polysorbates (PS) are surface active ingredients, 
which are commonly supplemented to biopharmaceutical formulations with intention of 
preventing aggregation. They are heterogenous mixtures of a PEGylated sorbitan core with 
one or multiple esterified fatty acids. Although PS molecular mechanism of action is well 
investigated, it is to this date still not clear how different quality grades compare in 
stabilizing proteins. Moreover, impact of (partly) degraded PS on protein stability is not fully 
understood. In this thesis, a monoclonal antibody (IgG) was subjected to pumping, stirring 
and dropping stress, which mimic applied mechanical stresses to a proteinaceous drug 
product during manufacturing, transportation and administration. Protein was formulated 
with two PS 80 quality grades, one compliant with Ph.Eur., USP and JP, and the other in line 
with stricter ChP. Furthermore, the antibody was supplemented with (partly) hydrolyzed PS 
80. LC-CAD was performed to confirm successful degradation and to assess PS 80 
concentrations used in this study. Surfactant functionality was assessed by measuring the 
extent of protein aggregation. Particles in nano- and micro-meter size range were 
characterized by using particle characterization techniques, such as micro-flow imaging 
(MFI), backgrounded membrane imaging (BMI) and dynamic light scattering (DLS). 
Additionally, turbidity and soluble protein aggregates were analyzed by using UV 
spectroscopy and ultra-high performance size exclusion chromatography (UP-SEC), 
respectively. We noticed a concentration range, where PS 80 is effective. No discrepancy in 
functionality was observed for two quality grades. Fully degraded PS 80 does not possess 
any stabilizing properties. When a portion (more than ~10 %) of neat PS is degraded, this 
results in poorer protection of the antibody under mechanical stress. Similarly, presence of 
extra degradants at the same intact PS 80 concentration was found to be destabilizing.  More 
studies should be carried out with focus on development of repeatable stress methods and 
examination of oxidized PS functionality. 
Key words: polysorbate 80, polysorbate degradation, IgG stability, aggregation, mechanical 
stress testing, particle analysis  
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Povzetek 
Kompleksna tridimenzionalna zgradba terapevtskih proteinov in njihova nagnjenost k 
agregaciji so velik izziv za biofarmacevtska podjetja, saj lahko proteinski agregati vzbudijo 
imunske reakcije, prekinejo pretok manjših žil in vodijo k zmanjšanju količine proteinskih 
monomerov, ki so odgovorni za terapevtski učinek. Proteinski agregati so skupki proteinskih 
monomerov, ki se lahko razlikujejo v velikosti, strukturi in reverzibilnosti. Njihov nastanek 
lahko sproži nihanje temperature, neugoden pH, prisotnost oksidativnih radikalov ali pa 
mehanski stres, kot je na primer tresenje, mešanje, strižne sile ali padec na trdno podlago. 
Znanih je več mehanizmov tvorbe proteinskih agregatov. Eden najpomembnejših je 
agregacija na mejnih površinah, kjer pride do konformacijske spremembe proteina zaradi 
adsorpcije na medfazo (npr. zrak-tekočina ali trdna snov-tekočina). Spremembe v strukturi 
proteina (sekundarne, terciarne, kvarterne zgradbe) vodijo do odkrivanja hidrofobnih 
področij, ki so bolj dovzetna za interakcije kot površina nativne konformacije proteina. 
Deformirana struktura proteina služi kot povod za agregacijo na medfazi. Agregacija na 
medfazi je še posebej močno izražena v kombinaciji z mehanskim stresom, ki prekine 
adsorbiran film proteina na medfazi in proteinske agregate prenese v raztopino, kjer le-ti 
sprožijo nadaljnjo agregacijo. 
Polisorbati so površinsko aktivne snovi, ki so pogosto prisotne v formulacijah s proteini z 
namenom preprečevanja agregacije. So heterogene zmesi mono- ali poli-estrov 
polioksietiliranega sorbitana z višjimi maščobnimi kislinami. Številne študije opisujejo 
mehanizem njihovega delovanja v smislu preprečevanja agregacije. Adsorpcija polisorbatov 
na mejne površine in s tem kompetitivno zaviranje adsorpcije proteina na le-te je glavna pot 
preprečevanja agregacije. Poleg tega sta v literaturi opisana še dva mehanizma. Prvi 
predpostavlja vezavo polisorbatov na hidrofobna področja proteina. Na ta način pride do 
zmanjšanja interakcij med samimi proteini ter med proteinom in medfazo. Drugi pa 
predpostavlja, da je delovanje polisorbatov podobno molekularnim šaperonom, ki proteinu 
olajšajo in omogočijo spremembo konformacije nazaj v nativno. 
Čeprav je mehanizem delovanja polisorbatov dobro raziskan, še vedno ni popolnoma jasno, 
kako različne stopnje kakovosti, ki ustrezajo specifikacijam iz različnih farmakopej, vplivajo 
na stabilnost proteinskih formulacij. Vpliv razgradnih produktov polisorbatov na stabilnost 
proteinov prav tako ni dobro raziskan. Znano pa je, da so polisorbati nagnjeni k razgradnji, 
najpogosteje po oksidativni poti zaradi faktorjev kot so UV svetloba, prisotnost reaktivnih 
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kisikovih zvrsti in kontaminacije s prehodnimi kovinami (Fe, Cu). Druga možna pot 
razgradnje je hidroliza, ki v farmacevtsko relevantnih pogojih poteče zaradi encimov, ki 
izhajajo iz celic, uporabljenih v proizvodnem procesu in so prisotni zaradi nezadostnega 
čiščenja proteina.  
V magistrskem delu je bilo monoklonsko protitelo IgG izpostavljeno mehanskemu stresu 
treh različnih izvorov. Prvi mehanski stres je bil povzročen s črpanjem raztopine v sistemu 
dveh injekcij, ki sta bili povezani s kapilaro. Za vzbuditev drugega mehanskega stresa smo 
uporabili mešalnik s 96 individualnimi mešalnimi lopaticami. Zadnji mehanski stres smo 
povzročili s prostim padom viale na trdno podlago. Le prva metoda mehanskega stresa je 
bila ustrezna za primerjavo vpliva različnih koncentracij, stopenj kakovosti in razgradnih 
produktov polisorbata 80 na stabilnost monoklonskega protitelesa, kar je bil tudi namen te 
magistrske naloge. 
Uporabljenemu proteinu smo dodali polisorbat 80 dveh različnih stopenj kakovosti. Prva 
stopnja kakovosti je ustrezala specifikacijam evropske, ameriške in japonske farmakopeje, 
druga pa strožjim specifikacijam kitajske farmakopeje. Modelnemu proteinu smo dodali tudi 
(delno) razgrajen polisorbat 80, ki je bil pripravljen z bazično katalizirano hidrolizo. 
Uspešnost razgradnje polisorbata 80 je bila ovrednotena s tekočinsko kromatografijo, 
sklopljeno z detektorjem CAD (LC-CAD). Vpliv površinsko aktivne snovi na stabilizacijo 
proteina je bil analiziran z merjenjem stopnje njegove agregacije. Delci v nano- in mikro-
metrskem velikostnem razredu so bili proučeni z metodami, kot so pretočna mikroskopija 
(MFI), slikovna obdelava z membrano v ozadju (BMI) in dinamičnim sipanjem laserske 
svetlobe (DLS). Poleg tega smo motnost raztopine določali z UV-spektroskopijo, topne 
agregate pa z velikostno izključitveno kromatografijo ultra visoke ločljivosti (UP-SEC).  
Z metodo črpanja smo določili območje koncentracij polisorbata 80, kjer je le-ta učinkovit 
pri preprečevanju agregacije proteina. Za stabilizacijo proteina je bila potrebna koncentracija 
0.004 % (m/V) polisorbata 80. Ugotovili smo tudi, da je uporaba koncentracij polisorbata 80 
pod kritično micelarno koncentracijo (< 0.0017 % m/V) lahko neugodna. Za te raztopine 
smo namreč po stresu pri nekaterih ponovitvah določili večjo število agregatov v primerjavi 
z raztopino brez dodatka polisorbata. Z uporabo iste metode za vzbuditev mehanskega stresa 
smo primerjali tudi delovanje polisorbata 80 dveh različnih stopenj kakovosti pri treh 
izbranih koncentracijah. Polisorbat 80 je protein stabiliziral v podobni meri pri obeh stopnjah 
kakovosti in vseh treh preizkušenih koncentracijah. Za metodo s črpanjem je bila 
ugotovljena velika deviacija med posameznimi ponovitvami, zato predlagamo ponovitev 
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poskusov s polisorbatom 80 različnih stopenj kakovosti s ponovljivo metodo mehanskega 
stresa. Literatura prikazuje, da polisorbat 80, ki ustreza kitajski farmakopeji oksidira hitreje 
kot polisrbat 80 druge uporabljene kakovosti. Iz tega vidika bi bilo potrebno izvesti nadaljnje 
poskuse z uporabo oksidiranega polisorbata 80 in ugotavljanjem njegove aktivnosti.  
Pri analizi hidroliziranega polisorbata 80 smo ugotovili, da je prišlo do popolne hidrolize, 
saj je bil signal mono- in poli-estrov polisorbata 80 zanemarljiv v primerjavi z nerazgrajeno 
obliko. Dodatni signali v kromatogramu razgrajenega polisorbata 80 so najverjetneje 
pripadali prostim maščobnim kislinam. To domnevo smo potrdili z MFI, ki je zaznala veliko 
število majhnih delcev, ter z BMI. Proste maščobne kisline so lipofilne, zato jih BMI 
membrana prepušča, kar je bilo v literaturi opaženo že za kapljice silikonskega olja.  
Vpliv razgrajenega polisorbata 80 na stabilnost proteina smo preizkušali z mehanskim 
stresom, povzročenim s črpanjem. Ugotovili smo, da popolnoma razgrajen polisorbat 80 ne 
prepreči agregacije, saj smo z MFI in BMI določili zelo veliko število nastalih agregatov. 
Pomanjkanje učinkovitosti polisorbata 80 lahko pripišemo izgubi amfifilnega značaja.  
V nadaljevanju smo razgrajenemu polisorbatu 80 pri nespremenjeni celokupni koncentraciji 
dodajali večji delež nerazgrajenega polisorbata. Šele pri 90 % deležu nerazgrajenega 
polisorbata 80 je bilo število delcev enako kot pri 100 % nerazgrajeni obliki. Iz tega lahko 
razberemo, da imamo lahko le ~10 % razgrajenega polisorbata 80 za želen stabilizacijski 
učinek. V naslednjem poskusu smo stalni koncentraciji nerazgrajenega polisorbata 80 
dodajali različno količino razgradnih produktov. Večja količina dodanih razgradnih 
produktov je povzročila nastanek večjega števila proteinskih agregatov. To pomeni, da 
prisotnost večje koncentracije razgradnih produktov (prostih maščobnih kislin) negativno 
vpliva na stabilnost monoklonskega protitelesa.  
Na podlagi naših rezultatov in obstoječe literature predlagamo, da je koncentracijo 
polisorbata 80 potrebno izbrati zelo skrbno. Prenizka koncentracija je lahko neučinkovita ali 
celo negativno vpliva na stabilnost proteina. V primeru previsoke koncentracije pa le-ta 
sodeč po literaturi lahko povzroči hitrejšo razgradnjo/agregacijo proteina. S časom pa pri 
večjih koncentracijah tvegamo tudi prisotnost večjega števila razgradnih produktov, ki imajo 
prav tako neugoden vpliv na stabilnost proteinskih formulacij.  
 
Ključne besede: polisorbat 80, razgradnja polisorbatov, stabilnost protitelesa IgG, 
agregacija, preizkus na mehansko obremenitev, analiza delcev 
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1. Introduction 
1.1. Stability of protein therapeutics 
In the past two decades there has been an explosive growth in biopharmaceutics, especially 
with respect to monoclonal antibodies. The clinical use of therapeutic proteins has made the 
treatment of a wide range of life-threatening diseases possible, among them also those 
considered fatal only a few decades ago (1,2). Compared to small pharmaceutical molecules, 
proteins are significantly larger molecules with a complex three-dimensional structure and a 
greater degree of heterogeneity (1). Development and manufacturing of biopharmaceuticals 
is therefore challenging and involves overcoming numerous manufacturing obstacles related 
to the poor stability of the proteins (2). A particular concern is the formation of protein 
aggregates, which can trigger formation of anti-drug antibodies after repetitive 
administration (1). Unwanted immune response towards the biopharmaceutical can affect 
drug safety, efficacy and pharmacokinetics, which may put the patient´s safety at risk (3). 
Aggregates are generally defined as assemblies of protein monomers and can vary in many 
aspects, such as size, reversibility, and structure (4). Disruption of protein structures 
(secondary, tertiary, quaternary) exposes their hydrophobic regions, susceptible for 
interaction, leading to unwanted aggregation (5). Formation of aggregates can be triggered 
by either temperature fluctuations, unfavorable pH, presence of oxidative radicals, or 
mechanical stress conditions, such as shear stress, shaking, stirring and dropping (1,5,6,7).  
There are various mechanistic pathways leading to the final result of aggregation. One may 
be significant for a specific protein but is negligible for another. Moreover, several 
mechanisms can concomitantly contribute to aggregates formation. Nevertheless, protein 
aggregation at the interfaces is one of the most noteworthy mechanisms where the affected 
protein undergoes a conformational change due to the adsorption to the interface (e.g., air-
liquid or solid-liquid) (Figure 1). The resulting non-native conformation serves as a starting 
point for aggregation in solution or directly at the surface (8). Interface aggregation is 
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especially prone to occur in combination with mechanical stress which deforms or perturbs 
the interfacial protein layer (7,9). 
 
 
Figure 1: Demonstration of interface-induced aggregation of an antibody. In the first step protein 
adsorbs to the interface (solid-liquid or liquid-liquid interface is also possible), followed by structural 
perturbation and aggregation at the interface. Upon mechanical stress aggregates are released into 
the bulk solution. Adapted from Rudiuk et al. (10). 
 
Although, the biopharmaceutical industry has made a great effort to stabilize 
biopharmaceutics during manufacturing and prolong their shelf life by producing robust 
formulations, protein products still encounter many interfaces during manufacturing, 
transportation and clinical administration, which can result in protein aggregation (2,9,11). 
The level of particulates and protein aggregates can be assessed during quality control prior 
to batch release, but once the product is released and shipped there is just little control left 
over the numerous factors that may affect the stability of these delicate products (2). 
1.1.1. Compendial specifications for solutions for parenteral 
administration 
In order to ensure patient’s safety, European Pharmacopoeia (Ph.Eur.) and United States 
Pharmacopoeia (USP) have set harmonized requirements on particle load in formulations 
intended for parenteral administration. Currently, particle concentrations within size ranges 
≥ 10 µm and ≥ 25 µm are specified in both Pharmacopoeias, which are summarized in table 
I (12,13). Even though Ph.Eur. and USP do not impose limits on particle concentrations for 
particles of size  10 µm, the United States Food and Drug Administration (FDA) expects 
particulates in the size range of 2-10 µm to be evaluated by using techniques currently fitting 
for characterization of particles in this size range. Additionally, the FDA states, that effort 
should be made to characterize particles in the size range of 0.1-2 µm. These 
1. Adsorption of 
antibodies at the 
interface
2. Interface-induced 
structural perturbation 
followed by 
aggregation at the 
surface
3. Release of 
aggregates in the 
solution upon 
mechanical 
perturbation
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recommendations are of great importance, as protein particles (0.1-10 µm in size) have a 
strong immunogenic potential (14,15,16). 
Table I: Requirements of Ph.Eur. and USP on particle concentration within solutions for parenteral 
administration; Two compendial techniques are described with respective limits of particle counts. 
Container’s total volume 
Analytical 
technique 
Limit for mean 
particle count 
 ≥ 10 µm 
Limit for mean 
particle count  
≥ 25 µm 
 100 ml 
Light obscuration 25 per ml 3 per ml 
Membrane 
microscopy 
12 per ml 2 per ml 
≤ 100 ml 
Light obscuration 
6,000 per container 600 per 
container 
Membrane 
microscopy 
3,000 per container 300 per 
container 
 
1.1.2. Analytical techniques for particle characterization 
The harmonized compendial technique used for quantification of particles for parenteral 
solutions in the micro-meter size range is light obscuration (LO). The measurement 
principle of LO is based on the obscuration of light caused by particles in the solution, which 
is illuminated by a laser beam in a sensing zone. A decrease in light intensity, proportional 
to cross-sectional area of the particles is recorded by the photodetector. The cross-sectional 
area is dependent on size and orientation of the particle. Considerably low linear range of 
quantification is due to the fact, particles have to pass a laser beam individually. Moreover, 
calibration of LO instruments is performed with polystyrene beads which have a higher 
refractive index compared to proteinaceous particles. Counts for highly translucent protein 
particles can be therefore underestimated. Air-bubbles can impede the results as well, as they 
are detected as particles. 
Ph. Eur. and USP’s compendial technique membrane microscopy is to be used, if a 
solution’s viscosity or turbidity hampers the characterization by LO. In addition, this 
technique is performed, when data obtained from LO does not meet the particle limits 
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specified in table I. Membrane microscopy is performed by firstly filtrating the solution 
through a membrane. Next, caught particles on the membrane of size larger than 10 µm and 
25 µm are identified and counted manually by the operator, thus making it bias and time-
consuming. By using membrane microscopy translucent proteinaceous particles can be hard 
to detect and higher particle concentrations difficult to count. In contrast with LO, air 
bubbles are eliminated from analysis upon filtration. Despite some disadvantages of both 
compendial techniques, they are widely used for controlling particle load in protein 
pharmaceutics (12,13,17). 
Other analytical systems are broadly used for characterization of micrometer sized 
particulates. Flow-imaging techniques, for instance, utilize a flow cell, where multiple 
particles can be distinguished at once, which results in higher limit for particle quantification 
compared to LO. In addition, particles are imaged by a charge-coupled device camera giving 
information on shape, transparency and compactness of the particles. There are several flow-
imaging systems currently on the market such as Micro-flow imaging (MFI, Proteinsimple, 
San Jose, CA, USA) and FlowCAM (Fluid imaging Technologies, Scarborough, ME, USA). 
Compared to LO, this imaging technique is more sensitive towards particles showing a minor 
difference of refractive index to that of the surrounding fluid. Nonetheless, refractive index 
is still a concern, since minor discrepancies in refractive indices can be a reason for larger 
particles to be split into numerous smaller fractions during software analysis. With aid of 
captured images, air-bubbles can be to some extent excluded from analysis (17,18). 
A new analytical technique for assessment of particles in micro-meter size range, which 
combines imaging and filtration features is backgrounded membrane imaging (BMI, 
Horizon, Halo Labs, Philadelphia, PA, USA). This is an automated system, which utilizes 
96-well plate format filter membrane, on which particles are imaged upon filtration step. 
Horizon automatically subtracts the membrane background and provides particle 
concentration along with particle images. The 96-well plate used for sample preparation 
offers a high throughput characterization and the software-based analysis reduces the risk of 
operator bias in particle quantification. 
Turbidity measurements are used regularly for comparisons of samples, as this technique 
is non-destructive, high-throughput and low sample volume is needed. Turbidity data does 
not provide any information on concentration, origin or size of particles. Consequently, only 
relative changes in aggregation can be assessed (17). 
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Dynamic light scattering (DLS) is suitable for particle analysis in the size range 1 nm-
10 µm. This technique is based on brownian motion of the particles, where larger particles 
are moving slowly compared to fast moving small particles. The solution analyzed by DLS 
is illuminated with a laser light which is scattered by the analyte and for which intensity 
fluctuations are determined. The fluctuations in the intensity of scattered light are determined 
by using an autocorrelation function, which compares primary scattering intensity to the 
intensity after defined time periods. A slow decay is due to slow fluctuations from large 
particles and oppositely a fast decay due to the fast fluctuation in signal from presence of 
small particulates. From the decay rate a diffusion coefficient can be determined and used 
for calculation of particle radius via Stokes-Einstein equation. Intensity-weighted mean 
hydrodynamic size (Z-average) and polydispersity index (PDI) are calculated in addition and 
are usually reported for DLS analysis (17). 
Size exclusion chromatography is a robust method for quantification of protein monomer, 
fragments, oligomers and small soluble aggregates. Also, an indirect estimation of fraction 
of insoluble aggregates as a loss in the total monomer peak area is possible. High sensitivity 
and low volumes are main attributes of this method (17).  
Further techniques are used for protein particle characterization (e.g. coulter counter, 
nanoparticle tracking analysis, fluorescence microscopy), but are not described, as they were 
not used for our experiments.  
 
Figure 2: Overview of analytical techniques in nano- and micro-meter size range used for particle 
characterization in this study. Adapted from Zölls et al. (17). 
  
DLS
UV Spectroscopy
BMI
MFISize exclusion
chromatography
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1.2. Formulations of protein therapeutics 
1.2.1. Surface active ingredients 
Surface active ingredients (surfactants) are amphiphilic molecules, which means they 
possess a hydrophilic and a lipophilic character. The latter part of the molecule is usually 
consisting of long chained hydrocarbons. In contrast, the polar head differs quite heavily 
between different surfactants. Based on the hydrophilic part, surfactants can be divided into 
two groups: nonionic and ionic. Surfactants in the latter group can carry either negative or 
positive charge, which is typical for amphoteric (i.e. zwitterionic) surfactants (19). Because 
of their dual nature, surface active ingredients tend to adsorb to interfaces and by doing so 
they are lowering the surface tension. When all of the interfaces are saturated, they start to 
assemble in the bulk solution to form micelles (spherical aggregates of a surfactant). This 
happens when concentration of a surfactant is above the critical micelle concentration 
(CMC) (20). Hydrophilic-lipophilic balance (HLB), a measure of the degree to which a 
surfactant is hydrophilic or lipophilic, is obtained by multiplying the quotient of molecular 
mass of the hydrophilic portion with total molecular mass of the molecule by 20. Surface 
active ingredients are used as detergents, antifoaming, emulsifying, wetting, spreading, 
solubilizing and lastly stabilizing agents (19). 
1.2.1.1. Polysorbates 
Polysorbates (PS, trade name Tweens) are amphiphilic nonionic surface-active ingredients 
commonly used for prevention of biopharmaceutical related instability occurrences, leading 
to e.g., protein aggregation. Polysorbate 20 and 80 are used to stabilize around 80 % of all 
monoclonal antibody products currently on the market (21). This is due to their high surface 
activity at low concentrations, which is achieved by a high HLB value and a low CMC 
(0.0017 % weight per volume (w/v) for polysorbate 80). Approval by regulatory agencies 
for parenteral administration because of their low toxicity support their common use 
(20, 21). Typical concentrations for PS in biopharmaceutical products are between 0.001 % 
and 0.1 % w/v, equivalent to 0.01 mg/ml and 1 mg/ml. In addition to polysorbates, other 
surfactants are used for parenteral application, such as poloxamers, sodium dodecyl sulfate, 
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lecithin, Solutol HS 15, Cremophor and alkylsaccharides. However, they are used just in a 
minority of the biopharmaceuticals (21). 
1.2.1.2. Polysorbate structure 
Polysorbate 80 (PS 80) has theoretically a defined structure related to its formal name: 
polyoxyethylene (20) sorbitan monooleate (sorbitan core and polyethylene glycol (PEG) 
side chains esterified with a single oleic acid) (Figure 3). However, in practice, it is a mixture 
of chemically diverse molecules limited in their structure heterogeneity by demands of 
different Pharmacopoeias. The core of the PS 80 molecule comprises of either sorbitan or 
isosorbide ring and together with attached polyethylene glycol chains (PEG) they provide 
the hydrophilic segment of the surfactant. The average total number of PEG subunits 
(w+x+y+z) is equal to 20. On the other hand, hydrophobic properties are provided by the 
fatty acid chains, esterified with PEG chains. Oleic acid composes the main fraction of fatty 
acids in PS 80, with 18 carbon atoms and at least 58 % fraction, according to European 
Pharmacopoeia (Ph.Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia 
(JP). Since 2015 Chinese Pharmacopoeia (ChP) established new requirements for injectable 
grade PS 80, where  98 % of oleic acid content is required. Other acids, such as linoleic, 
palmitic and palmitoleic acids are present to a lesser extent and are viewed as impurities 
(Table II). Heterogeneity of the structure comes not only from fatty acid composition but 
also from esterification in one or more hydroxyl group of the side PEG chain. Currently, 
Ph.Eur., ChP, USP and JP do not restrict in number of esterified hydroxyl groups attached 
to PEG chains. Therefore, three main PS 80 fractions can be distinguished within neat 
polysorbate: non-esterified species (free PEG chains attached to either sorbitan or isosorbide 
core), once esterified fraction (mono-esters) and lastly fraction esterified with two or more 
fatty acids (poly-esters). Furthermore, degradation products and impurities, such as free fatty 
acids (FFAs), fatty-acid esters, PEG chains, sorbitol, non-esterified sorbitan and isosorbide, 
aldehydes, ketones, etc., which derive from synthesis and storage, may also be present in 
native polysorbate products (21). 
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adsorption and subsequent aggregation at interfaces. This protective effect is strongly related 
to the critical micelle concentration (CMC) of the PS (21,23,27). In addition, binding to 
hydrophobic areas on the protein surface through weak hydrophobic interactions and thus 
hampering protein-protein or protein-interface interactions, have been proposed (23). In 
some studies, the latter mechanism was deemed negligible and aforementioned competitive 
mechanism was found to be responsible for most of the monoclonal antibody stabilization 
(24). On the contrary, Arsiccio et al. and Deechongkit et al. observed molecular mechanisms 
involving PS binding to the protein are significant. They have shown this pathway is not 
CMC dependent, as aggregation prevention was seen already below CMC (23,25). Further, 
Bam et al. implied another mechanism where polysorbates act like molecular chaperones, 
catalyzing the native folding of the protein and thus preventing aggregation (26). Last-
mentioned stabilizing mechanism was confirmed, where it was proposed protein complex 
formed through polysorbate binding to the hydrophobic regions on the protein surface is the 
initial step for both inhibition of protein unfolding and support in protein refolding (23). 
 
1.2.2. Forced degradation studies 
Developing an optimal formulation for therapeutic proteins is a crucial step for gaining 
approval from regulatory agencies. Selecting an appropriate formulation requires screening 
of different buffers and surfactants, that will best protect the respective protein from stress 
factors, such as temperature/pH changes, freezing, thawing, light exposure, mechanical 
stress etc. This is accomplished by forced degradation studies, which involve subjecting 
various formulations to stress conditions in order to identify the most stable one. By using a 
combination of forced degradation methods, stability of a formulation can be better assessed, 
as one excipient can be either stabilizing or destabilizing in response to a different stress 
condition. Mechanical stress methods (e.g. shear stress, stirring and dropping stress) are 
among stress conditions, which can cause unwanted aggregation in biopharmaceutic 
products (28). 
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1.2.2.1. Shear stress 
Surface exposure, especially throughout manufacturing often goes together with shear stress 
arising from fluid flow. Mechanical shear stress during manufacturing stages and 
administration can vary heavily in duration and magnitude. Shear from 50 Hertz in the low-
range during mixing stages, typically lasting from minutes to hours, up to thousands of Hertz 
during filling and filtration is applied to biopharmaceutics. Additionally, upon 
administration proteins are exposed to high shear rates in thin needles (9,29). Recently, 
Thomas et al. in a review paper reported mechanical shear is rarely or never primary cause 
for protein aggregation and suggested other interfacial effects are notably contributing to the 
final outcome of formed proteinaceous particles (30). Dobson et al. have in addition 
demonstrated shear stress alone is most likely not sufficient to provoke aggregation but that 
this is rather due to extensional flow causing elongation of the protein molecule (31). They 
also pointed out, the ability of shear stress and extensional flow to cause aggregation is 
protein dependent. For instance, globular proteins are believed to be insensitive to shear 
stress. 
 
1.2.2.2. Stirring stress 
Stirring stress is frequently applied in forced degradation studies of biopharmaceuticals to 
mimic interfacial stress during manufacturing. Contact stirring can generate protein 
aggregates possibly due to shear stress, interfacial effects, cavitation and local thermal 
effects (5). Recently, Sediq et al. suggested a key pathway of proteinaceous aggregates 
formation under contact stirring stress (7). They have demonstrated contact stirring leads to 
substantial aggregation, since sliding of the stirring bar abrades the adsorbed protein layer 
(consisting of (partially) defolded monomers or aggregates), releasing (partially) defolded 
monomers or aggregates into the solution, where it could further promote particle formation. 
After removal of adsorbed protein layer by the stirring bar, cycle of protein adsorption, 
abrasion and aggregation repeats. For non-contact stirring they proposed air-liquid interface 
is the root cause for particle formation. The suggested pathway for contact stirring involves 
greater solid-liquid interface stress, which explains why non-contact stirring was found to 
be gentler in comparison with contact stirring (7). 
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1.2.2.3. Dropping stress 
Commonly overlooked mechanical stress is caused by unintentional drop of the pre-filled 
syringes or vials with the protein product. Whether it happens to a patient or a caregiver, 
those events are usually not recognized as potentially damaging. Randolph et al. 
demonstrated, that a fall from only 25 cm on a solid surface can cause cavitation and 
possibly damage the protein (6). Cavitation is the rapid formation, growth, and collapse of 
vapor bubbles within a liquid. As a dropped container hits a solid surface, the solution inside 
experiences mechanical shock and shock waves are created. Accordingly, areas with really 
low pressure and bubbles are formed as a result of liquid transitioning from its liquid state 
to a gaseous state. With the rapid collapse of the formed bubbles areas of higher pressure 
“hot spots”-regions of extremely high temperatures and pressure are created. Furthermore, 
hydrogen and hydroxyl radicals are formed due to the collapse. Consequently, high 
temperature, high pressure and free radical formation that occur during cavitation can 
damage the protein molecules (6). 
 
1.3. Polysorbate oxidation and hydrolysis 
Chemical stability of the PS is an important concern for their use, as they are known to 
undergo various degradation mechanisms, such as oxidation and hydrolysis (20,21). The 
former is the most common and can be induced by various factors including ultraviolet (UV) 
light, heat, reactive oxygen species (ROS), arising from residual dissolved or head space 
oxygen and peroxides, and finally transition state metal impurities (predominantly Fe and 
Cu). Oxidation of PS shows an initial lag phase where little to no PS degradation can be 
detected and is followed by formation of degradants such as peroxides, oxidized fatty acids 
and short-chain organic acids (20,21,32). Koch et al. have demonstrated a complex role of 
histidine, which was showing a protective effect against hydrogen peroxide mediated 
oxidation. In contrast, possibly due to contained impurities, oxidation was promoted (32). 
They concluded, that complex inter-reliant mechanisms between buffer excipients, 
impurities and proteins play a significant role in respect to degree and rate of PS oxidation. 
Chemically induced PS hydrolysis catalyzed by basic or acidic conditions was observed for 
forced degradation studies, however under relevant pH conditions it is not very probable to 
occur. In contrast, enzymatically induced hydrolysis of the ester bond, driven by host cell 
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proteins (HCPs) copurified with therapeutic protein, was found to be plausible under 
pharmaceutical relevant conditions (33,34). Examples of such HCPs include lipoprotein 
lipase, putative phospholipase B like 2 and phospholipase A2 (34). Degradation products 
emerging from hydrolysis are free fatty acids and non-esterified sorbide (isosorbide) rings 
with PEG chains (21,32). 
1.4. Considerations for polysorbates use in 
biopharmaceuticals 
The final biopharmaceutical product´ s quality and stability could be hampered by presence 
of byproducts from the manufacturing process of PS (e.g. free fatty acids) as well as various 
PS degradants (35). In literature it was reported, FFAs deriving from PS neat material or 
possibly PS degradation, can potentially result in particulate matter formation during storage 
at 4 C, due to their low solubility in aqueous buffers. Siska et al. proposed a mechanism of 
solubilization of FFA particles, where PS can seclude FFA molecules by incorporation in 
micelles (35) (Figure 4). By doing so, neat PS material is able to prevent accumulation of 
insoluble particles to a certain molar ratio (35,36). Remaining insoluble particulates could 
be either just a cosmetic matter, or they could serve as a starting point for protein 
aggregation (35). 
Kishore et al. demonstrated a negative impact on monoclonal antibody stability under 
shaking stress in presence of free lauric acid (36). Supplementation of lauric acid at the same 
PS 20 intact concentration resulted in major increase in formation of visible particles, visual 
opalescence and soluble aggregates content upon shaking (36). However, in the same study 
they also performed end-of-shelf-life shaking experiments with aged (partially degraded) 
PS 80 and have shown, partially degraded surfactant does not cause protein aggregation. 
Furthermore, they also discovered that artificially oxidized PS 20/80, added to the protein 
formulations at different molar ratios, does not impair protein stability, when a threshold 
intact PS concentration is present (36). As data on degradants’ impact on protein stability is 
very limited to this date, further studies should be carried out to investigate this dilemma. 
Moreover, like protein aggregates, PS 80 particulates have shown potential 
immunogenicity (37).  
In summary, due to poorly investigated effect of PS-related particles on protein stability and 
possible safety issue, care should be taken to avoid PS-particulates in protein formulations. 
 
13 
It is therefore vital to select highest purity of PS for formulations, that are intended for 
injection. Care should be taken to store neat PS at room temperature or lower, protected from 
light and exchanged head space oxygen with nitrogen, to prevent the potential oxidation. 
Diluted PS solutions should be always prepared freshly, used instantly and discarded after 
manufacture in order to avoid oxidation, which is accelerated by higher diffusion coefficient 
in dilutions. In practice it is common to add more PS than it is actually required for 
stabilization of therapeutic proteins to ensure there is sufficient amount of the surfactant 
present throughout the lifetime of a protein product. Conversely, unwarranted amount of the 
PS should be avoided to prevent accelerated protein product degradation (21,22). 
 
 
Figure 4: Schematic drawing of fatty acid molecules, solubilized in PS micelles. Adapted from Doshi 
et al. (38). 
Polysorbate 80
Fatty acid
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2. Work plan 
In this thesis an IgG monoclonal antibody will be subjected to pumping, stirring and 
dropping stress, while supplemented with Ph.Eur. or ChP compliant PS 80, as well as (partly) 
hydrolyzed PS 80. Liquid chromatography coupled with charged aerosol detector (LC-CAD) 
will be performed to confirm successful degradation and to assess PS 80 concentrations used 
in this study. Aim of this thesis is to determine the influence of PS 80 concentrations, quality 
grades and degradants on the stabilization of IgG monoclonal antibody. Surfactant 
functionality will be assessed by measuring the extent of protein aggregation. Particles in 
nano- and micro-meter size range will be characterized by using particle characterization 
techniques, such as micro-flow imaging (MFI), backgrounded membrane imaging (BMI) 
and dynamic light scattering (DLS). Additionally, turbidity and soluble protein aggregates 
will be analyzed by using UV spectroscopy and ultra-high performance size exclusion 
chromatography (UP-SEC), respectively. Using this set of analytical techniques particles in 
nano- and micro-meter size range can be comprehensively assessed (Figure 2). 
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3. Materials and methods 
3.1. Materials 
A monoclonal antibody IgG formulated at 50 mg/ml in 12 mM L-histidine, 8.8 % (w/v) 
D(+)-sucrose buffer, pH 6.0 was used in this study. Polysorbate 80 in agreement with United 
States, European and Japanese Pharmacopoeia was purchased from J.T. Baker (Avantor, 
Center Valley, PA, USA) and polysorbate 80 in line with Chinese Pharmacopoeia was from 
Croda International Plc (Snatih, Goole, United Kingdom). D(+)-saccharose and Acetonitrile 
were purchased from VWR Chemicals (Radnor, PA, USA) and L-histidine from Sigma 
Aldrich (Taufkirchen, Germany). 1 M Hydrochloric acid, 1M Sodium hydroxide, 25 % 
Ammonia solution, Di-sodium hydrogen phosphate dihydrate, Sodium dihydrogen 
phosphate dihydrate and Sodium sulfate were obtained from Merck (Darmstadt, Germany). 
Formic acid was from Biosolve B.V. (Valkenswaard, the Netherlands). Methanol was 
purchased from J.T. Baker (Avantor, Center Valley, PA, USA) and Isopropanol from Fischer 
Scientific (Hampton, NH, USA). Water used in the present study was particle free, highly 
purified water (conductivity: 18.2 mΩ·cm), compliant with the Ph.Eur. 1927 monograph. It 
was obtained from water purification system equipped with 0.22 µm filter (Milli-Q® IQ 
7000 or Milli-Q® Advantage A10 system; Merck, Darmstadt, Germany). 
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3.2. Methods 
3.2.1. Mechanical stress testing 
3.2.1.1. Syringe pump test 
Application of mechanical shear stress mimicking filling, pumping, sterile filtration on 
protein samples was carried out by using a neMESYS apparatus (Heinzelmann et. al., patent: 
US7, 916,289 B2; 2011) equipped with Hamilton-Gastight syringes (Hamilton SYR 10 ml, 
1010 TLL, Bonaduz, GR, Switzerland), placed in custom 3D printed holders. The syringes 
consisted of glass barrel and a plunger coated with polytetrafluoroethylene (PTFE). A 20 cm 
PEEK capillary (Thermo Scientific, Waltham, MA, USA) with inner diameter 0.25 mm, 
0.75 mm or 1 mm in U-shape was placed between both syringes and was fitted to each one 
via luer lock adapter (Combifix, B. Braun, Melsungen, Germany). Left syringe was filled 
with 3,3 ml of the sample and subsequently the pumping motion was initiated. Solution in 
the left syringe was pumped to the right one passing the capillary where mechanical shear 
stress was created. The right syringe was operating in exactly inverse fashion to the left one. 
A complete cycle included uptake and release of a single syringe. During the pumping 
motion, the PTFE plunger was positioned just above the headspace filled with air over the 
solution in the syringe. Due to concave shape of solution meniscus, the plunger was touching 
the liquid surface at the edges of the syringe barrel. The lowest position of the plunger was 
when 90 % of the filled volume was released. Different capillaries and flow-rates were 
assessed during method development to alter the applied shear stress. Additionally, number 
of cycles was adapted to obtain number of particles not requiring dilutions for analysis of 
stressed samples. Before stressing IgG solutions, placebos (buffer with or without addition 
of PS) were subjected to the mechanical stress in the system to guarantee there was no 
contamination from previous experiments and demonstrate no PS-related particles were 
formed in the system. The components of the system (syringes, capillary and luer lock 
adapters) were thoroughly cleaned after either placebo or IgG pumping run with 10 % 
Hellmanex, ethanol and highly purified water. Second controls included in the study were 
non-stressed IgG solutions. Samples were analyzed by using micro-flow imaging, 
backgrounded membrane imaging, UV spectroscopy, dynamic light scattering and ultrahigh 
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performance size-exclusion chromatography. Parameters of the method used for 
experiments presented if not stated otherwise were as follows: 
Table III: Parameters of syringe pump test 
Pumping stress method 
Capillary ID 1 mm 
Flow-rate 8.84 ml/min 
Fill volume 3.3 ml 
Time pattern 17 s 
Period 34 s 
Applied shear stress 1500 s-1 
Duration 56 min 40 s 
 
3.2.1.2. Stirring 
Non-contact stirring stress was induced by using a precise micropaddle mixer (Micropaddle 
IMP-096A, Ulvac Solutions, Japan), equipped with 96 individual paddles and a 96 well plate 
(Corning Incorporation, NY, USA). 200 µL of the sample was filled per well and single 
columns consisting of the same tested sample were exposed to a fixed stirring rate, with 
rotation speed accuracy ±1 %. Placebo samples were filled in at least two columns for each 
experimental setup. Stirring paddles were cleaned prior to generation of stirring stress using 
10 % Hellmanex, ethanol and highly purified water. Unstirred samples were used as second 
controls. Initially rotation speeds from 100 to 3,000 rotations per minute (rpm) were tested 
over 4h at room temperature. Due to negligible increase in particle concentration for PS 80 
containing samples, stirring time was prolonged up to 36h. Two silicone sheets (5 mm and 
7 mm of thickness) were tested allowing different mixing paddle protrusion lengths. With 
5 mm sheet, paddle was mixing approximately in the center and with 7 mm just under the 
surface of the respective sample solution. After stress treatment, entire 96 well plate was 
analyzed using UV spectroscopy. Next each well was analyzed using backgrounded 
membrane imaging and later each column (ca. 1,360 µL) was transferred to a 2 R sterile vial 
for further analysis by micro-flow imaging and dynamic light scattering. 
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3.2.1.3. Free-fall drop test 
Free-fall drop impact test was carried out by using an in-house designed apparatus which 
meets the specifications of “Needle-based injection systems for medical use-Requirements 
and test methods-Part 1: Needle-based injection systems” listed in ISO 11608-1, third 
edition, 15. Dec. 2014. Sterile 2 R vials filled with 1,5 ml of IgG sample were subjected to 
the free-fall drop test. The vial fell freely from a height of 1,000 mm on a test surface made 
out of smooth, hard rigid steel of 3 mm thickness, backed by wood whose thickness was 
20 mm. Custom 3D printed vial holder enabled the vial to fall on a test surface at an 45° 
angle. The holder was released in a tube, which assured the dropping was executed in a non-
turbulent way. Undropped IgG solutions in identical vials were used as controls. Samples 
were analyzed using micro-flow imaging, dynamic light scattering and UV spectroscopy. 
3.2.2. Sample preparation 
3.2.2.1. Dilution buffer 
Formulation buffer contained 12 mM L-histidine and 8.8 % (w/v) D(+)-saccharose at pH 6.0 
(adjusted with 1 M hydrochloric acid). After preparation it was filtrated through 0.22-µm 
PVDF membrane filter (durapore membrane filter GV, Merck, Darmstadt, Germany) and 
stored at -40 oC until used. 
3.2.2.2. Preparation of polysorbate 80 stock solution 
Stock solution of PS 80 in formulation buffer was prepared as follows: The respective 
amount of surfactant was weighed accurately in the volumetric flask to obtain target 
concentration 4 % (w/v). Next, surfactant was dissolved completely in formulation buffer 
and lastly flask was precisely filled up to the mark. Stock solution was aliquoted into 2 ml 
cryotubes and stored at -80 oC until required. Concentration of the stock solution was verified 
with LC-CAD. 
 
19 
3.2.2.3. Preparation of hydrolyzed polysorbate 80 
In a 10 ml volumetric flask 50 mg of PS 80 was accurately weighed. 2.125 ml of LC-MS 
grade methanol and 375 µL of 1M sodium hydroxide (NaOH) was added and mixed well by 
using vortex. Prepared solutions of both quality grades of PS 80 were incubated at 40 °C for 
21 hours in an Eppendorf Thermomixer Comfort (Hamburg, Germany). After incubation 
leftover NaOH was neutralized with 10 % (w/w) formic acid (172 µL) and thereafter the 
volumetric flask was filled up with methanol to the mark. Subsequently the solution was 
divided into 1,5 ml Eppendorf safe-lock tubes (500 µL per tube). Methanol was removed by 
a RVC 2-18 CD plus SpeedVac (Martin Christ) operating at 37 °C over 2 hours with 
1,400 rpm. Dried, hydrolyzed PS 80 was resuspended in 500 µL of formulation buffer, 
diluted ten-fold with buffer and analyzed by using LC-CAD. Non-degraded control with the 
same amount of PS 80 but with no addition of NaOH or formic acid was included and 
analyzed for PS 80 content. 
3.2.2.4. Preparing samples 
IgG was stored at -80 oC in 2 ml cryogenic nalgene tubes (Thermo Scientific, Waltham, MA, 
USA) until needed. IgG aliquots were thawed at room temperature until no visible ice 
crystals were observed and homogenized by careful pipetting. The required amount of 
sample was diluted to ca. 7 mg/ml and thereafter IgG content was confirmed using Nanodrop 
One C (Thermo Scientific, Waltham, MA, USA) by measuring the absorbance at 280 nm 
(E1 %: 1.51 l·mol-1·cm-1). Solution was filtrated through 0.22-µm PVDF membrane filter 
units (Millex-GV, Merck, Darmstadt, Germany). Later appropriate volumes of stock PS 80 
(4 % w/v) were added to reach target PS 80 concentration. Finally, formulation buffer was 
used to dilute the sample further to 5 mg/ml. Along with IgG containing samples, 
corresponding placebos were prepared for each experiment. Handling of the samples 
throughout the entire study was carried out solely under laminar air flow conditions. For 
sample preparation air displacement along with Multipette (Eppendorf, Hamburg, Germany) 
pipettes with sterile tips were used.  
For this thesis, two main studies were carried out, firstly by using intact PS 80 and secondly 
by using intact and hydrolyzed PS 80 in addition. Sample preparation for neat PS study is 
described above. Two separate experiments were performed with supplementation of 
degraded PS 80 (PS 80 degradation study I and II). In the PS 80 degradation study I, total 
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PS 80 concentration was kept constant at 0.01 % w/v. The difference between individual 
prepared solutions was in the content of degraded PS 80 ranging from 10 %-100 %. For 
sample with 90 % degraded PS 80 concentration of neat PS 80 was 0.001 % w/v and fully 
degraded PS 80 at 0.009 % w/v. For preparation of samples, first appropriate volume of 
intact PS 80 and thereafter degraded PS 80 was spiked to reach 0.01 % w/v when combined.  
In the PS 80 degradation study II intact multicompendial polysorbate 80 (MCPS 80) 
concentration was kept constant at 0.009 % w/v with variable volume of added degradants. 
First included sample was supplemented with respective volume, that resulted in final 
0.001 % w/v degraded MCPS 80 concentration in the solution. The second and third sample 
contained 0.002 % w/v and 0.003 % w/v concentration of degraded MCPS 80, respectively. 
As in the degraded PS 80 study I, hydrolyzed PS 80 was added after supplementation with 
intact PS 80. 
3.2.3. Liquid chromatography with charged aerosol detection 
(LC-CAD) 
Ultimate 3000 (Dionex, Sunnyvale, California, USA) high pressure liquid chromatography 
(HPLC) system coupled to Corona Veo charged aerosol detector (Thermo Scientific, 
Waltham, MA, USA) was used for PS 80 composition and content analysis. With Waters 
BEH C18 column (50x2.1 mm, 300 Å pore size, 1.7 µm particle size) (Milford, 
Massachusetts, USA) heated to 60 °C separation was performed. 10 µL of sample was 
injected and analyzed over 15 minutes with mobile phase flow rate 0.9 ml/min. Gradient 
settings for mobile phase over time used for analysis are shown in table IV. For detection by 
CAD automatically adjusted nitrogen pressure, desolvation temperature 50 °C and CAD 
output range 100 picoamperes (pA) were used. PS 80 content was quantified with aid of 
calibration curve with 0.1 %, 0.075 %, 0.05 %, 0.025 %, 0.01 %, 0.005 % w/v solutions of 
PS 80 made with volumetric dilutions of 1 % w/v stock solution in formulation buffer. 
Integration was executed in Chromeleon Chromatography Data System V6.8 software 
(Thermo Scientific, Waltham, MA, USA). 
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Table IV: Mobile phase gradient during HPLC-CAD analysis. Phase A: Highly purified water, 
Phase B: Acetonitrile, Phase C: Highly purified water, 2 % (v/v) formic acid, 0.0064 % (w/v) 
ammonia hydroxide, Phase D: Isopropanol. 
Time 
(min) 
Mobile phase (%) 
A B C D 
0.0 85.0 10.0 5.0 0.0 
9.8 13.7 81.3 5.0 0.0 
11.0 0.0 14.2 5.0 80.8 
12.0 0.0 14.2 5.0 80.8 
12.01 0.0 95.0 5.0 0.0 
12.5 0.0 95.0 5.0 0.0 
12.51 85.0 10.0 5.0 0.0 
15 85.0 10.0 5.0 0.0 
 
3.2.4. Micro-flow imaging (MFI) 
MFI 5200, (Proteinsimple, San Jose, CA, USA) was used to analyze particles of more than 
2 µm in size. Particle diameter was reported as equivalent circular diameter. System was 
operating with a 100 µm flow cell. To confirm particle free conditions in the cell a water test 
was performed by using highly purified water. The instrument was ready to use if ≤ 200 
particles per milliliter (p/ml) with an equivalent circular diameter (ECD) larger than 2.00 µm 
and ≤ 1 particle with ECD larger than 10 µm were detected. In addition, a measurement with 
a COUNT-CAL 5 µm particle size standard was carried out, to affirm sizing and counting 
precision of the instrument. 0.7 ml of the standard was analyzed, and 0.2 ml was used for 
purging. Instrument was deemed for use if particle concentration was within 10 % of the 
manufacturer specification. Before each sample measurement illumination was optimized 
with formulation buffer. Using a Neptune filter tip (Biotix Inc, San Diego, CA, USA), 
0.55 ml of the sample was carried over to the instrument preserving particle free conditions 
during the analysis. 0.17 ml of the sample volume was used to purge, and 0.28 ml of the 
volume was analyzed. Between measurements flow cell was flushed with 3 ml of highly 
purified water, removing any trace of prior sample. Data was exported with MVSS V2-
R4.2.0.42 and processed with MVAS V2.3 (Proteinsimple, San Jose, CA, USA). Particles 
of less than 2.0 µm in size and particles either imaged on the edges of the cell or stuck to the 
 
22 
cell walls were excluded from analysis. Remaining particles were divided in multiple size 
ranges with 0.25 µm bin sizes. 
3.2.5. Backgrounded membrane imaging (BMI) 
Horizon (technology Backgrounded Membrane Imaging, Halolabs, PA, USA), was used as 
a complementary method to micro-flow imaging for sub-visible particle sizing and counting 
analysis. Horizon system consists of an imaging system and vacuum apparatus for sample 
preparation. Samples were applied on a polycarbonate 96 well membrane filter plates 
(Halolabs, PA, USA) with 0.4 µm pore sizes. First a background image of the filter plate 
was taken. Next samples were pipetted in triplicates under laminar air flow conditions on 
the surface of the membrane, 30 µL per well. For higher particle concentrations in stressed 
samples 5-20 fold dilution with buffer was necessary to stay within the linear range of 
quantification. The controls always included on the plate surface along with samples were: 
three empty wells for air control and three wells with highly purified water. After placing 
sample to 3 wells vacuum was applied at 350 mbar below ambient pressure for liquid 
removal. Next, each well was washed with 90 µL of highly purified water to prevent sticking 
of the membrane to the vacuum manifold. Lastly the back of the filter plate was dried by 
using drying cassette with wicking paper. For particle analysis the same membrane was 
imaged again, this time with caught particles on the membrane surface. The software 
(Horizon VUE image analysis software V.1.2.2.1 and V.1.3, Halolabs, PA, USA) 
automatically subtracted the background acquired in the first step and analyzed particle 
counts of more than 2 µm in size. Particle diameter was reported as equivalent circular 
diameter. Counts of particles in p/ml were exported in four size ranges (2-5 µm, 5-10 µm, 
10-25 µm and ≥ 25 µm). 
3.2.6. UV Spectroscopy 
Tecan Safire II basic plate reader (Tecan Austria GmbH, Grödig, Austria) was used for 
detection of protein content at 280 nm and to assess turbidity of the formulations at 350 nm. 
UV measurements were performed in triplicates in 96-well plates (Corning Incorporation, 
NY, USA). 200 µL of sample volume was pipetted into each well. In addition to sample 
measurements, blank measurements with formulation buffer were performed. The 
background absorbance was corrected by subtracting blank measurements from sample 
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measurements by using absorbance values that were corrected for the corresponding 
pathlengths. Samples for determination of protein content were gravimetrically diluted to a 
protein concentration of 1 mg/ml prior to the analysis, to obtain target absorbance by using 
filtered formulation buffer. A280 values were corrected for scattering by subtracting 
absorbance at 320 nm. The protein concentration was calculated by using A280-A320 value 
and a specific absorbance coefficient of 1.51 l·mol−1·cm−1. Undiluted protein concentration 
was acquired after correction with the dilution factor. Optical density of undiluted samples 
was determined at 350 nm to assess turbidity. For these values no corrections were 
performed apart from subtraction of the absorbance of formulation buffer. All Path-corrected 
values were collected in the Maggellan V6.3 software (Tecan Austria GmbH, Grödig, 
Austria). 
3.2.7. Dynamic light scattering (DLS) 
Zetasizer APS 2000 plate reader (Malvern Instruments, Worcestershire, UK) was used for 
analyzing particles in nano-meter size range. Individual wells on a 96 well plate (Corning 
Costar, New York, United States) were filled with 150 µL of sample volume. Measurements 
were performed by using automatic measurement mode at 25°C and an angle of 90° in 
triplicates. The Malvern Zetasizer Software V 7.03 (Malvern Instruments, Worcestershire, 
UK) was used to fit the autocorrelation function using the default settings for protein 
solutions and water (refractive index = 1.333; viscosity = 0.890 mPa*s) to calculate Z-
average diameter, polydispersity index (PDI) and intensity-weight based particle size 
distribution. Numerical data was exported from the Zetasizer software. Graphs and digits 
reported are the average of triplicate measurements.  
3.2.8. Ultra-high pressure size-exclusion chromatography 
(UP- SEC) 
For the UP-SEC analysis, an Acquity ultra performance liquid chromatography (UPLC) 
system (Waters Corporation, Milford, MA, USA) equipped with an UV detector was used. 
Prior to analysis samples were diluted with formulation buffer to a final protein 
concentration of 2 mg/ml and were thereafter centrifuged with 13,000 x g for 3 minutes. 
Supernatant was isolated and transferred into HPLC vials with micro glass inserts. 
Separation was performed on a TSK gel UP-SW3000 column (4.6 x 150 mm, 2 µm particle 
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size) (Tosoh Bioscience, Tokyo, Japan) with an isocratic flow 0.22 ml/min. Mobile phase 
consisted of 150 mM sodium sulfate and 100 mM sodium phosphate dihydrate (61.3 and 
38.7 mM sodium and Di-sodium respectively) buffer at pH 6.8. Monomer, higher and lower 
molecular weight species were analyzed at 215 nm wavelength. Data was evaluated in 
Empower 3 software (Waters Corporation, Milford, MA, USA). The performance of the 
UPLC column was tested with Biorad gel (containing thyroglobulin, gamma globulin, 
bovine serum albumin, myoglobin, and vitamin B12) filtration standard (Hercules, CA, 
USA). 
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4. Results 
First, acquired data from the syringe pump stress method are presented, which was carried 
out for comparing functionality of Chinese Pharmacopoeia compliant PS 80 (ChPS 80) and 
multicompendial PS 80, compliant with European, United States and Japanese 
Pharmacopoeia (MCPS 80), as well as investigating effect of (partly)degraded PS 80 on IgG 
stability. This mechanical stress method was chosen, due to substantial particle 
concentrations generated, which were suitable for intended comparisons. Stirring and 
dropping stress on the contrary did not significantly increase particle concentration for IgG 
samples containing PS 80. Therefore, were not deemed appropriate for PS 80 functionality 
evaluation.  
Since DLS did not reveal any adequate changes in nano-meter range, especially for PS 80 
supplemented samples this method was left out for further experiments (quality grade 
comparison and degraded PS 80 study), as it would not provide us with any additional 
information.  
In every figure or table shown in this chapter, MCPS 80 and ChPS 80 are labeled only by 
MCPS and ChPS. Similarly, for PS 80 concentration percentages they are not marked 
additionally with w/v, but they always refer to w/v concentration. 
4.1. LC-CAD 
Concentration of PS 80 and extent of PS 80 hydrolysis was assessed by using LC-CAD with 
a method developed by Koch et al. (32). Neat PS 80 consisted of three main fractions: 
Free PEG, mono-esters and poly-esters. Using the mobile phase gradient profile, free PEG 
eluted earliest at ~1-5 minutes. Mono-esters followed with retention time from ~7-9.9 
minutes and poly-esters eluted last at ~10.5-12.5 minutes. Determination of neat PS 80 
content in prepared aliquots, stored at -80 C was carried out by using 6-point calibration 
curve, as discussed in materials and methods. LC-CAD revealed that MCPS 80 and ChPS 80 
sample, diluted to theoretical value of 0.01 % w/v, contained 0.0098 % w/v and 0.0099 % 
w/v of PS 80 on average, respectively. Relative standard deviation was below 1.5 % between 
each set of samples for respective quality grade. Absence of signal within the mono- and 
poly-ester fractions’ regions indicated complete hydrolysis of PS 80. For both PS 80 quality 
 
26 
grades, poly-esters were almost completely gone with remaining 3-5 % of initial signal 
surface (below limit of detection) for neat PS 80 at the same concentration. Peak for mono-
esters was also severely decreased for both quality grades however, in their retention time 
window a signal initially not present in neat PS 80 chromatogram appeared. Therefore, it 
can be concluded, it originated from degradation reaction. Along with a signal decrease for 
esterified fractions, an increase was detected for free PEG fraction for MCPS 80 and 
ChPS 80. In addition, the non-degraded PS 80 control sample with no spiking of NaOH 
showed a chromatogram equal to that of neat PS 80 at 0.05 % w/v (Figure 5). 
 
 
Figure 5: LC-CAD chromatograms of degraded PS 80 in comparison with neat PS 80 at the same 
concentration. Time dependent signals are presented in picoamperes (pA). A distinct decrease in both 
poly- and mono-ester signals and an increase in free PEG signal is presented. Species resulting from 
hydrolysis are eluting at ~8.0 and ~9.0 minutes. 
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4.2. Pump syringe stress 
4.2.1. Method development 
4.2.1.1. Micro-flow imaging 
Three capillary tubings (ID: 0.25 mm, 0.75 mm and 1 mm) were tested with set flow-rate at 
18.41 ml/min over 1 h at room temperature. The system was filled with 2.5 ml of the IgG 
solution supplemented with 0.04 % w/v MCPS 80. For the follow up experiments, sample 
volume was increased to 3.3 ml to suffice for intended analytical characterization. Placebo 
runs were included in each experimental setup. Stressed placebos were monitored 
throughout the study to ensure cleanliness of the system and observed particle counts were 
up to 7,000 p/ml in the study using only neat PS (data not shown). In contrast, pumping of 
any sample containing protein product resulted in the formation of extensive amount of 
particles, which confirmed proteinaceous origin of formed particulates under pumping stress 
with all tested parameters. Non-stressed IgG sample spiked with MCPS 80 to target 
concentration of 0.04 % w/v for method implementation presented particle concentration, 
that was sufficiently low. 10-fold dilution using formulation buffer was necessary prior to 
measurement of stressed samples to stay within the linear range of quantification (Figure 6). 
Substantial number of particles was detected for stressed IgG solution with the capillary of 
smallest diameter (~1,000,000 p/ml). Analysis of samples pumped through the 0.75 mm and 
1 mm capillaries exhibited particle concentrations that were noticeably lower: ~200,000 p/ml 
and ~100,000 p/ml, respectively. The difference was considerably smaller for particles 
greater than 5 µm in size. For particles with an ECD larger than 10 µm, counts were higher 
when solutions were pumped through wider capillaries, compared to generated particle count 
with the thinnest capillary.  
Our goal was to develop a method, where no dilutions of stressed samples would be 
necessary for analysis. Therefore, lower shear stress was required. Settings for other 
experiments in this thesis were altered. Method, that applied low shear stress (1,500 Hertz) 
was used for follow-up experiments, in the continuation referred to as pumping stress 
method. 
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particle formation in syringe pump stress was seen at concentrations above or equal to 
0.004 % w/v, most clearly for particles with an ECD in the range 2 µm-5 µm. Conversely, 
when PS 80 was spiked at sub-CMC concentrations (0.0008 % and 0.001 % w/v), detected 
particle concentrations for stressed IgG solutions were considerably higher. Further, stressed 
IgG samples with no supplementation of PS 80 presented particle concentrations (above 
2 µm, 5 µm and 10 µm) that were in some cases lower compared to stressed IgG samples 
supplemented with sub-CMC PS 80 concentrations. MCPS 80 and ChPS 80 supplemented 
at the same concentration did not demonstrate substantial differences in particle 
concentration in any size-range.  
With respect to morphology of particles, a difference was observed for PS-free samples in 
comparison with samples containing PS 80. Dark flake-like particles were imaged by using 
MFI in PS-free and PS 80 containing formulations, whereas translucent fiber-like particles 
were observed only in PS-free samples (Figure 13). 
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b)
 
Figure 7: Average concentrations of micrometer sized particles determined by using MFI. Y-axis on 
the left represents particle concentrations for stressed samples, while the one on the right represents 
particle concentrations for all “IgG non-stressed” samples. a.) MCPS 80 concentration range 
(0.0008 %, 0.004 %, 0.008 %, 0.04 % w/v) along with PS-free formulation is presented b.) 
Comparison MCPS 80 vs. ChPS 80 at three different concentrations (0.001 %, 0.01 % and 
0.1 % w/v). 
 
4.2.2.2. Backgrounded membrane imaging 
BMI was performed for comparing particle counts in micro-meter size range to those 
obtained by MFI. Sample measurements were carried out for IgG solutions supplemented 
with either MCPS 80 or ChPS 80 at 0.001 %, 0.01 % and 0.1 % w/v. Results of triplicate 
experiments with standard deviation (SD) are shown in Figure 8. BMI yielded comparable 
results to MFI. MCPS 80 and ChPS 80 supplemented at the same concentration 
demonstrated similar particle concentration after stress. On the other hand, there was a 
difference in obtained particle counts for stressed samples containing 0.001 % w/v PS 80 
and those containing 0.01 % or 0.1 % w/v PS 80. 
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Figure 8: Average concentrations of micrometer sized particles determined by using BMI. Y-axis on 
the left represent particle concentrations for stressed samples, while the one on the right represents 
particle concentrations for all “IgG non-stressed” samples. Comparison MCPS 80 vs. ChPS 80 at 
three different concentrations (0.001 %, 0.01 % and 0.1 % w/v) Concentrations presented are 
corrected for dilutions. 
 
4.2.2.3. Dynamic light scattering 
Analysis of particles in the nano-meter range was carried out by DLS for PS-free and 
MCPS 80 supplemented IgG solutions (Figure 9). Non-stressed proteinaceous samples were 
monodisperse (PDI < 0.19) and Z-average was ca. 7.2 nm. There was no additional peak 
present in unstressed formulations. After applying mechanical stress to IgG sample with no 
PS 80, sample became more polydisperse (PDI 0.37  0.05). In addition, the Z-average 
increased when compared with unstressed formulations (Z-average for stressed IgG solution: 
12.4  1.8 nm) and two additional peaks appeared at 600 nm and 1760 nm. Stressed samples 
supplemented with PS 80 remained monodisperse, however a small increase in PDI was 
observed for low PS 80 concentrations (0.0008 % and 0.001 % w/v). For one formulation 
with higher MCPS 80 concentration (0.01 % w/v) the PDI increased very slightly. Other 
formulations with higher PS 80 concentrations exhibited no change compared to unstressed 
controls.  
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Figure 9: Intensity-weighted size distribution of non-stressed representative sample (1st row, left 
column) along with formulations subjected to pumping stress containing PS 80 (1st row right column 
-4th row left column) and no PS 80 (4th row right column) are presented. Detected size of particles 
measured with DLS in nm (x-axis) is plotted against their relative intensity in % (y-axis). Z-average 
and PDI with SD of triplicate measurements are shown for each sample. 
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4.2.2.4. UV Spectroscopy 
By measuring the absorbance of the solution at 280 nm and 350 nm protein concentration 
and turbidity was determined, respectively. IgG concentration was 4.87 mg/ml for non-
stressed PS 80 supplemented and PS-free samples with relative standard deviation 4 % 
between samples. After stress treatment, the protein concentration decreased to an average 
of 4.75 mg/ml with 3 % deviation among included samples. Turbidity of three chosen 
concentrations for MCPS 80 and ChPS 80 was measured to assess degree of aggregation 
(Figure 10). Non-stressed samples showed an average value of ~0.01 OD350 nm. For 
formulations containing 0.001 % PS 80 and 0.01 % w/v PS 80 turbidity increased for ca. 
0.01 OD350 nm after stress, irrespective of PS quality grade, with exception of sample 
containing 0.001 % w/v ChPS 80, where slightly higher average difference of 
0.017 OD350 nm was recognized. A minimal increase compared to lower PS 80 
supplemented solutions in A350 value was observed for 0.1 % w/v PS 80 formulation, where 
for MCPS 80 a bigger increase of 0.004 OD350 nm was measured. There was a good overall 
correlation between data in micro-meter range and measured increase in turbidity, even 
though increase in turbidity was not substantial. 
 
 
Figure 10: Turbidity measured at 350 nm for stressed and non-stressed IgG formulations containing 
either MCPS 80 or ChPS 80 at 0.001 %, 0.01 % and 0.1 % w/v is presented. Average values with SD 
are shown for triplicate experiments. 
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4.2.3. PS 80 degradation study I 
4.2.3.1. Micro-flow imaging and Backgrounded membrane imaging 
Fully hydrolyzed PS 80 at 0.01 % w/v, of both PS 80 quality grades, demonstrated 
substantial amount of insoluble degradants with an ECD larger than 2 µm, when measured 
with MFI (Figure 11). By using orthogonal techniques a difference in concentrations of 
particles per ml with a size above 2 µm was observed for placebos. Namely, measured 
particle concentrations of particles bigger than 2 µm by BMI were below 10,000 for each 
degraded PS 80 content (Figure 12). Concentrations of particles for unstressed IgG 
formulations containing degraded PS 80 are not presented separately, as they closely 
resembled counts for corresponding unstressed placebo solutions. A non-linear decrease in 
particle concentration was seen for unstressed placebos, when intact PS 80 content increased. 
Concentration of particles with an ECD larger than 2 µm in 100 % degraded PS 80 placebo 
was ~17 times higher when compared to the 50 % degraded PS 80 placebo sample. On 
account of MFI analysis of placebo runs, it was difficult to evaluate whether the system was 
particle-free before each IgG run due to high initial counts (50-100 % degraded PS 80 
samples). In addition, BMI was performed for stressed placebos and showed low number of 
particles (data not shown). Pumped placebo samples, measured by MFI, supplemented with 
10 % and 25 % degraded PS 80 did not present more than 7,000 p/ml with an ECD 
above 2 µm. 
To assess functionality of 100 % degraded PS 80, fully hydrolyzed PS 80 at 0.01 % w/v was 
spiked into IgG solution and subjected to pumping stress. Amount of formed aggregates in 
the micro-meter size range after stress treatment for triplicate experiments (with SD) or 
single experiments (without SD) was determined by using MFI and BMI (Figure 11,12). In 
the presence of fully hydrolyzed PS 80 of both quality grades, high particle concentration 
(with emphasis on cumulative concentration for particles above 2 µm) was recorded for 
stressed IgG solutions by using MFI. Even though, non-stressed 100 % degraded PS 80 IgG 
samples already presented elevated counts of particles, concentration of particles for stressed 
sample was so high, that even after subtraction of initial counts concentration was still ~8 
times higher in comparison to sample supplemented with the same amount of neat PS 80 and 
stressed under equivalent conditions. BMI similar to MFI revealed very obvious formation 
of particles in 100 % degraded PS 80 samples, especially for the population with size 
above 2  
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Figure 13: Exemplary particles imaged by using MFI. A difference in morphology of proteinaceous 
particles can be seen after pumping stress for samples containing intact PS 80 and those with no or 
fully hydrolyzed PS 80 supplementation. 
 
4.2.3.2. UV spectroscopy 
Mean protein content was determined to be 4.88 mg/ml for non-stressed and 4.75 mg/ml for 
stressed samples, with relative SD of 3% in both instances. Non-stressed samples presented 
turbidity values of 0.01 to 0.02 OD350 nm, with exception of sample with spiked 90 % 
degraded MCPS 80, which initially exhibited 0.025 OD350 nm. The greatest increase 
(~0.03 OD350 nm) in turbidity was observed for samples with supplementation of 100 % 
degraded PS 80 of both quality grades. In presence of less than 90 % hydrolyzed PS 80 of 
either quality grade, the difference between stressed and non-stressed turbidity values was 
~0.02 OD350 nm, only in the presence of 50 % degraded ChPS 80 the increase was smaller 
(0.01 OD350 nm). Samples containing neat PS 80 along with those supplemented with only 
10 % degraded PS 80 presented a turbidity increase which was less or equal to 
0.01 OD350 nm. Turbidity data corresponds to data obtained by MFI and BMI, but observed 
increases were low for any sample included (Figure 14). 
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Figure 16: Effect of spiked PS 80 degradants at the constant neat MCPS 80 concentration of 
0.009 % w/v on particle concentration in sub-visible range measured by using BMI. Average and SD 
of triplicate experiments are shown for stressed samples. Presented concentrations are corrected for 
dilutions. 
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4.2.4.2. UV spectroscopy 
Baseline protein concentration was determined to be 4.96 mg/ml. It decreased to an average 
of 4.78 mg/ml after the applied stress, with relative standard deviation of < 2 % both in non-
stressed and stressed samples. Turbidity was measured to assess degree of aggregation in 
stressed samples (Table V). Value 0.010 OD350 nm was obtained for all samples before 
mechanical stress treatment. An increase in turbidity was observed for each sample 
submitted to syringe pump stress. Addition of more degraded MCPS 80 resulted in greater 
increase of A350 nm value. UV spectroscopy showed similar trends to data obtained by MFI 
and BMI. 
 
Table V: Effect of spiked PS 80 degradants at the constant neat MCPS 80 concentration of 
0.009 % w/v on turbidity at 350 nm. Mean values with SD are summarized for triplicate experiments. 
High standard deviation was observed for samples supplemented with 0.002 % and 0.003 % w/v 
degraded MCPS 80. 
IgG MCPS 80 degraded concentration (w/v) Mean absorbance (350 nm) ± SD (OD350 nm) 
0.001 % non-stressed 0.010 ± 0.001 
0.001 % stressed 0.014 ± 0.002 
0.002 % non-stressed 0.010 ± 0.005 
0.002 % stressed 0.021 ± 0.011 
0.003 % non-stressed 0.010 ± 0.006 
0.003 % stressed 0.032 ± 0.018 
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4.3. Stirring stress 
4.3.1. Micro-flow imaging 
Stirring stress was performed by using the ULVAC microstirrer equipped with a 96-well 
plate. A fixed stirring rate was applied to all wells within a single column. Initially, different 
rotation speeds were tested for PS-free IgG solution over 4 hours at room temperature with 
a 5 mm silicone sheet layer. Initial particle concentration of the solution was under 
1,000 p/ml for particles of size larger than 2 µm. Paddle rotation speeds at 2,500 rpm and 
3,000 rpm resulted in formation of protein aggregates. At lower speeds (below 2,500 rpm) 
no stirring-induced protein aggregation was observed (Figure 18). Consequently, 2,500 and 
3,000 rpm were selected for follow-up experiments. 
 
Figure 18: Effect of rotation speed on protein aggregation in micro-meter size range measured by 
MFI. Non-stressed samples are shown on the left side of the chart. Each stirred sample presents a 
column on a 96-well plate pooled for MFI analysis. Formulation buffer stirred at 3,000 rpm did not 
exhibit any increase in particle concentration. Stirring was carried out for 4h at room temperature 
using 5 mm silicone sheet. 
 
IgG solutions supplemented with MCPS 80 to target concentration 0.01 % w/v or 
0.001 % w/v were included along with PS-free sample for the next experiment carried over 
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(~15,000 p/ml), which was already observed for counts in PS-free solution before syringe 
pump stress and indicated high instability of the protein. All of the stirred placebos exhibited 
sufficiently low particle counts with exception of MCPS 80 at 0.01 % w/v. Two columns 
were filled with IgG solution containing no PS 80 (Figure 19). The mean particle 
concentration for particles of size larger than 2 µm of two individual columns was 
240,179 p/ml (relative deviation between two columns 44 %). Furthermore, stressed samples 
with PS 80 at 0.01 % or 0.001 % w/v exhibited just a minor increase in particle concentration. 
Also, columns did not compare for the same sample under equal conditions (relative 
deviation for 0.01 % w/v and 0.001 % w/v MCPS 80 supplemented samples for three 
columns within the same experiment was 96 % and 51 %, respectively) (Figure 19). 
 
 
Figure 19: Effect of stirring with the highest rotation speed (3,000 rpm) over 4 hours with 5 mm 
silicone sheet on aggregation of IgG samples with or without addition of MCPS 80. Average and SD 
of three columns on the stirring plate for MCPS 80 containing samples, and average and SD for two 
columns for PS-free sample are presented. Stressed MCPS at either 0.01 % or 0.001 % w/v and buffer 
were pooled from a single stirred column. 
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4.3.2. Backgrounded membrane imaging 
By using BMI, the extent of particle formation due to stirring stress within single wells was 
examined. Each color represents a set of one sample exposed to a single stress condition. 
Significant deviations can be observed within each set. Low repeatability was particularly 
evident for the sample with no PS 80, for which the relative deviation of 68 % was 
determined between individual wells (Figure 20). When MCPS 80 was added to the IgG 
solution, minor increase in particle concentration compared to non-stressed controls was 
noticed, therefore deviations between individual wells were correspondingly smaller in 
comparison with PS-free formulation. 
 
 
Figure 20: Particle concentration for particles with an ECD larger than 2 µm measured by BMI. 
Individual cells present wells on the stirring plate. 3rd, 4th and 5th column was filled with IgG 
MCPS 80 0.01 % w/v, 6th and 7th with PS-free formulation and 8th, 9th and 10th columns were filled 
with IgG MCPS 80 0.001 % w/v. Stirring was performed over 4 hours with 5 mm silicone sheet and 
3,000 rpm. Placebos were stirred in 1st, 2nd, 11th and 12th column, (data not shown). Ratio between 
the specific concentration and the highest concentration measured for respective solution is 
illustrated with bars. 
 
4.3.3. DLS 
For stirred proteinaceous MCPS 80 containing samples presence of nanometer sized 
particles was not detected by DLS. In contrast, samples with no addition of PS 80 presented 
a highly disrupted intensity-weighted size distribution. This technique, similar to MFI 
showed high variability between individual columns for PS-free solutions. An exemplary 
intensity-weighted size distribution of a single pooled column filled with PS-free sample is 
shown (Figure 21). 
3 4 5 6 7 8 9 10
A 867 2,600 2,367 621,533 362,433 1,200 1,467 1,433
B 1,767 2,900 1,533 799,200 305,500 2,467 2,367 1,533
C 3,167 3,000 2,333 277,367 767,133 1,133 2,100 6,300
D 1,500 2,767 2,233 586,433 376,000 1,633 2,267 2,000
E 2,167 2,333 1,367 45,167 392,000 1,300 1,267 1,867
F 2,367 2,967 1,567 68,900 1,008,067 2,367 3,067 4,133
G 2,267 2,533 4,100 356,133 741,033 2,133 2,433 9,867
H 3,100 2,700 2,900 96,267 103,233 3,533 2,633 2,300
IgG MCPS 0.01% IgG no PS IgG MCPS 0.001%
 
46 
 
Figure 21: Intensity-weighted size distribution of PS-free IgG solution stirred for 4h at 3,000 rpm 
with 5 mm silicone sheet. Detected size of particles measured with DLS in nm (x-axis) is plotted 
against their relative intensity in % (y-axis). Z-average and PDI with SD are shown for measured 
triplicates. 
 
4.4. Free-fall drop test 
4.4.1. Micro-flow imaging 
2 R vials filled with two different protein formulations (supplemented with 0.04 % w/v 
MCPS 80 and without PS 80) were subjected to one and multiple free-falls. Both 
formulations presented sufficiently low particle concentrations before stress. PS-free 
formulation showed elevated particle counts compared to the non-dropped sample after only 
a single free-fall. An increasing number of falls resulted in increasing particle concentrations 
for samples without surfactant. Observed trend was particularly evident for particles with an 
ECD larger than 2 µm. On the contrary, for MCPS 80 supplemented samples the number of 
particles with a size greater than 2 µm did not surpass 5,000 p/ml after any number of drops 
(Figure 22). 
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Figure 22: Effect of free-fall repetitions on particle counts in micro-meter size range measured by 
MFI. Stressed and non-stressed samples containing protein with 0.04 % w/v MCPS 80 or without 
PS 80 are presented. “F” stands for number of free-falls. 
 
4.4.2. DLS 
Particles formed upon dropping were characterized in the nano-meter size range by using 
DLS (Figure 23). Before stress all IgG solutions were monodisperse and presented 
monomodal distributions. The Z-average was between 7.3-7.6 nm and PDI was equal 
to 0.18. After one or two free falls no changes were observed for either formulations 
(proteinaceous samples supplemented with 0.04 % w/v MCPS 80 or without PS 80). After 
5 falls, samples with no PS 80 did not maintain the initial monodispersity (PDI 0.30  0.05) 
and the Z-average increased slightly (Figure 23), with an appearance of a second peak at 
~590 nm. Analysis after 10 falls depicted even greater increase for PS-free formulation for 
Z-average and PDI and revealed presence of a third peak at ~930 nm. Finally, after 20 drops 
sample containing no PS 80 showed the most disturbed intensity-weighted size distribution 
graph with three peaks and the highest corresponding Z-average and PDI values. On the 
contrary, in the presence of 0.04 % w/v MCPS 80 all samples remained monodisperse and 
Z-average was similar to non-stressed IgG samples. 
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Figure 23: Intensity-weighted size distribution of non-stressed samples (top row), samples subjected 
to 5 (2nd row), 10 (3rd row) and finally 20 falls (4th row). In the left column samples were 
supplemented with 0.04 % w/v MCPS 80 and in the right no PS 80 was added. Detected size of 
particles measured with DLS in nm (x-axis) is plotted against their relative intensity in % (y-axis). 
Graphs are scaled equally. Z-average and PDI with SD are shown for each sample for measured 
triplicates. 
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4.4.3. UV spectroscopy 
Protein concentration along with turbidity was determined by measuring absorbance. Protein 
content was 4.90 mg/ml on average for two non-stressed and 4.89 mg/ml for stressed 
solutions (1.3 % relative deviation between both stressed and non-stressed individual 
samples). At 350 nm turbidity was assessed (Table VI). Only for PS-free samples after 10 
and 20 falls a minor increase in mean absorbance value at 350 nm was detected. 
 
Table VI: Turbidity data with SD indicating measurement error at 350 nm for IgG solutions (with or 
without supplementation of PS 80) subjected to one or multiple free falls. Numerical data for 
undropped formulations is presented in addition. 
Sample name Mean absorbance (350 nm) ± SD (OD350 nm) 
IgG no PS non-stressed 0.013 ± 0.006 
IgG no PS 1F 0.014 ± 0.006 
IgG no PS 2F 0.013 ± 0.003 
IgG no PS 5F 0.013 ± 0.002 
IgG no PS 10F 0.017 ± 0.002 
IgG no PS 20F 0.019 ± 0.004 
IgG MCPS 0.04 % non-stressed 0.011 ± 0.004 
IgG MCPS 0.04 % 1F 0.012 ± 0.002 
IgG MCPS 0.04 % 2F 0.012 ± 0.005 
IgG MCPS 0.04 % 5F 0.012 ± 0.004 
IgG MCPS 0.04 % 10F 0.012 ± 0.004 
IgG MCPS 0.04 % 20F 0.009 ± 0.003 
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5. Discussion 
5.1. Pump syringe stress and functionality of MCPS 80 
In the present study we evaluated the syringe pump stress and observed high particle 
formation in proteinaceous samples irrespective of the presence of PS 80. By using different 
capillary IDs, we were able to demonstrate a distinct difference with respect to number of 
formed particles and obtained particle distribution. It was obvious, our setting with 0.25 mm 
ID capillary was generating more particles by including an additional aggregation-inducing 
factor. It is highly possible this factor was enhanced shear stress, as other parameters of the 
used method were equal as well as solid-liquid and air-liquid interface were present in each 
experimental setup. In spite of many reports in the literature suggesting shear is not a key 
factor for inducing aggregation (30,40), Biddlecomb et al. designed a shear apparatus and 
were able to show applied shear rates greater than 5,000 Hertz were resulting in protein 
monomer loss in presence of a solid-liquid interface (41). In addition, they demonstrated a 
strong correlation between increased shear rate and higher monomer loss. Our results are in 
agreement with their work, as we also found out higher shear was more damaging compared 
to low shear stress, meaning shear was a plausible key factor for aggregation in very high 
shear stress setting.  
For the pumping stress method, which was developed and used as a central part of this thesis, 
it was likely that shear alone was not the root cause for aggregates formation. Firstly, this 
was speculated by the fact there was a big difference in counts of particles for samples 
supplemented with MCPS 80 above or under CMC, which indicated interface-induced 
aggregation must have been taking place. Secondly, high particle concentrations obtained 
for samples supplemented with PS 80 subjected to low shear implied there were other factors 
contributing to aggregation, since in the literature shear strain within this range was not 
sufficient to cause aggregates formation (30,40,41). Surface-induced aggregation might have 
been due to the solid-liquid interface (glass, PTFE) or air-liquid interface. Out of both solid 
surfaces, PTFE was more likely to cause aggregation due to its hydrophobic chemistry as 
already reported in the literature (30). A possible mechanism of aggregates formation would 
be that protein readily adsorbed to surface of PTFE/glass, its structure was perturbed and 
was followed by aggregation. Formed aggregates were then scraped off into the bulk 
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solution, where further aggregation took place. The proposed pathway, leading to protein 
aggregation is mechanistically similar to the one suggested for contact-stirring in (7). 
From obtained particle data generated by pumping stress method we could conclude, that at 
least 0.004 % w/v of the MCPS 80 was needed for stabilization of the antibody during the 
stress we applied. Concentrations ranging from 0.004 % to 0.1 % w/v were able to stabilize 
our protein to a similar extent. Further, our particle data for samples containing sub-CMC 
MCPS 80 concentrations implied lack of stabilizing or even destabilizing effect on IgG, 
since greater aggregates formation was in some cases observed for sub-CMC supplemented 
samples compared to PS-free solutions. However, potential destabilizing effect was difficult 
to judge just from particle counts, since there was not only a difference in particle 
concentration but also a difference with respect to morphology of obtained particles in PS-
free and PS 80 containing samples. In absence of PS 80, solution already visually looked 
different (larger and longer aggregates were present) compared to PS 80 containing samples. 
MFI confirmed this observation and revealed two populations of particles for PS-free 
sample. The additional detected population was consisting of translucent, fibrous particles 
almost resembling a gel-consistency. The morphology discrepancy was never reported 
before but could be attributed to different mechanisms of aggregation. Darker, compact 
particles resembled those created by heat stress in combination with unfavorable pH or 
stirring stress in (42), whereas fiber-like translucent aggregates were imaged for agitation 
stress in (42) or seen after stress created by rupture of a protein film adsorbed to an 
interface (11). Possibly, PS 80 was sufficient in preventing a pathway that in the end led to 
fibrous particles.  
In the literature, there have been reports on destabilizing effects of PS 80 (although 
supplemented at 0.01 % w/v), which caused greater formation of small aggregates, measured 
by DLS in comparison to PS-free formulation under stirring stress (43). However, in our 
study DLS data showed enhanced particle formation for PS-free solution and in presence of 
PS 80 PDI and Z-average decreased. Moreover, UP-SEC did not reveal any major soluble 
aggregates for analyzed formulations. One possible explanation for this phenomenon would 
be, that aggregation induced by pumping occurred via intermediate nanometer sized particles 
and/or soluble aggregates, which were afterwards leading to generation of larger particles. 
These findings agree with findings from study (5), whereby using teflon coated stirring bars, 
IgG solutions were stirred in contact mode. Similar to our observations, DLS and UP-SEC 
in this study did not show much if any aggregates but stirred solutions did reveal major 
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increase in concentration of particles in micro-meter size range. Another common ground 
for our pumping stress in comparison with contact stirring using teflon bar in (5) is, that both 
methods were found to be very harsh and addition of PS 80 even at high concentrations was 
unable to fully prevent particles in micro-meter size range from forming. This could be 
because PS 80 was unable to cover all of the solid-liquid interfaces and/or is not effective 
against abrasion/scraping. 
5.2. Comparison in functionality of ChPS 80 and 
MCPS 80 
With aid of pump syringe stress our aim was to determine, if a difference in composition of 
both quality grades resulted in dissimilar stabilizing properties. Discrepancy in composition 
of PS 80 quality grades was revealed by LC-CAD, which showed different chromatograms 
indicative of different compositions. Since there has not been any reports in the literature 
with respect to the functionality of different PS 80 quality grades on stability of 
biopharmaceuticals, our research will serve as a base for future studies. We were not able to 
recognize a difference in functionality of MCPS 80 and ChP compliant PS 80. Sensitivity of 
both quality grades for degradation has to be considered, as this is highly relevant for 
preserving protein product’s quality. Koch et al. carried out experiments, where they were 
comparing susceptibility of Ph.Eur. and ChP grade PS 80 to oxidation and enzymatic 
hydrolysis (32). On one hand, they did not find a discrepancy in the speed of enzymatic 
hydrolysis when comparing both quality grades. On the other, they reported dissimilarities 
in susceptibility of MCPS 80 and ChPS 80 for oxidative degradation. In their study, PS 80 
in line with ChP was more prone to oxidation in the presence of hydrogen peroxide or iron 
ions in comparison to MCPS 80. This could be explained by higher levels of unsaturated 
oleic acid in ChPS 80. Nevertheless, they additionally showed that other parameters, besides 
the fatty acid composition, can determine the predisposition for oxidative degradation of PS, 
such as impurities introduced to the formulations (32). 
It was shown, that degradants arising from oxidative degradation were not provoking 
aggregation, if the threshold of intact PS concentration was still present (36). Even though 
oxidized PS species may not be destabilizing, if the oxidation is proceeding at such a high 
rate, it is likely no sufficient amount of intact ChPS 80 would be present at the end of the 
protein product’s lifetime. Therefore, it would be crucial to conduct further studies to better 
understand and monitor degradation of ChPS 80, before this new high purity grade PS 80 
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could be widely used in biopharmaceutic formulations (32). In addition, more studies with 
oxidized PS degradants should be carried out to gain a greater level of understanding on their 
impact on protein stability. 
5.3. PS 80 hydrolysis and functionality 
For evaluating functionality of degraded PS 80, artificially hydrolyzed PS 80 was prepared. 
Its composition was analyzed by using LC-CAD, which revealed peaks not present in neat 
PS 80 material. Products of PS hydrolysis are known to be sorbitan (or isosorbide) core with 
attached non-esterified PEG chains and free fatty acids released from fatty acid ester bonds. 
It is highly probable, that newly appeared peaks in LC-CAD chromatogram of degraded 
PS 80 belonged to FFAs, since LC-MS was performed for the same PS 80 hydrolysis 
protocol and revealed elevated amount of free fatty acids. Moreover, MFI analysis of 
degraded PS 80 solution showed high level of insoluble degradants, related to the poor 
aqueous solubility of free fatty acids, as reported in literature (21,22). Further evidence of 
degradants’ nature was provided by BMI, which was not able to show elevated particle 
concentration for placebo solutions containing degraded PS 80, as particles passed through 
the membrane during sample preparation. This phenomenon was already observed for 
silicone oil droplets measured by using BMI (39). However, it would be important to 
determine the identity of degradants as later in this thesis degraded PS 80 was used in 
formulations to study its stabilizing/destabilizing effect on IgG under mechanical stress. 
Other considerations for optimization of the PS 80 hydrolysis protocol included NaOH and 
formic acid, which were not filtered prior to addition, but as low volumes were used, we 
would not expect this to be the cause of insoluble material in degraded PS 80 solution.  
Our results from the pumping stress with supplemented fully hydrolyzed PS 80 in micro-
meter size range obtained by MFI and BMI clearly indicate, degraded PS 80 did not possess 
any stabilizing properties. In support of the numerical data, fiber-like translucent aggregates 
were imaged for IgG samples supplemented with 100 % of degraded PS 80, which were seen 
also in IgG formulation without addition of PS 80. Loss of the functionally of hydrolyzed 
surfactant can be attributed to lack of the dual (hydrophilic and hydrophobic) character and 
therefore, its ability to adsorb to interfaces and protect the protein from unfolding is reduced. 
The non-linear decrease in particle concentration for unstressed degraded PS 80 placebos 
could be due to the ability of intact PS 80 to solubilize the particles already present in the 
solution, possibly by sequestering them in micelles (35,36). It is likely, that intact PS 80 
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solubilized insoluble degradants initially present in solutions, and later, if sufficient amount 
of neat PS 80 was left, it protected the protein against pumping stress by adsorbing to the 
interfaces. We demonstrated, the content of degraded PS 80 in total PS 80 concentration 
could be just 10 %, for equal protection to 100 % intact PS 80 at the same concentration. 
In addition, with aid of artificially hydrolyzed PS 80, we were able to show a destabilizing 
effect of degradants (FFAs), since with greater addition of degradants at the same neat PS 80 
concentration more aggregates were detected. This finding may help us understand the effect 
of PS degradants on protein product’s stability, since it is not yet fully understood. Our data 
agrees with the lauric acid spiking study, where FFA (lauric acid) was supplemented at 
different molar ratios to neat PS concentration (36). It was shown that with increasing 
amount of lauric acid proteins aggregated to a greater extent under shaking stress. A possible 
explanation of this effect might be the tendency of the carboxylate functional group of the 
fatty acids to interact with the protein and neutralize the charge across the protein molecule 
due to the anionic character. As a result, increased self-association of the protein monomer 
could occur (44). Moreover, proteins adsorb to silicone oil-water interface resulting in 
conformational change, which enhances the possibility for aggregation (11,45). As FFAs 
share similar chemistry with silicone oil (high hydrophobicity), the same root cause for 
aggregation is present. Aggregation is especially prone to occur under mechanical stress, 
which deforms or perturbs the interfacial protein layer (11). Since we did not observe any 
major particle formation in PS 80 degradation studies before stress treatment but thereafter 
substantial aggregation was seen, our data agrees with the fact, that perturbation of an 
adsorbed protein film has a major impact on particle formation. This finding was also in line 
with lauric acid spiking study, where non-stressed solutions did not present elevated particle 
concentrations (36). However, our results from degradation studies do not agree with 
oxidized PS 80 study, where it was found out that threshold intact PS 80 concentration was 
able to compensate for abundant amount of degradants arising from oxidation (36). 
Likewise, in end-of-shelf-life stress studies with PS 80 they have shown that aged (degraded) 
surfactant was still able to prevent aggregation (36). Described discrepancies could be due 
to insoluble degradants (FFAs), which were present to a great extent in the present study but 
are not expected to form immensely due to oxidation or long storage under pharmaceutically 
relevant conditions (21,35). 
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5.4. Stirring stress 
As non-contact stirring was found to be gentler compared to contact stirring (7), low counts 
of particles in the micro-meter size range were anticipated in our setup with usual rotation 
speeds (50-600 rpm) used for forced degradation studies (28). 2,500 rpm was needed to 
initiate protein aggregation in PS-free formulations. PS 80 was highly efficient in preventing 
stirring-induced protein aggregation at all three tested concentrations (0.001 %, 0.01 %, 
0.04 % w/v), even under CMC. Protective effect of PS under CMC under agitation was 
already reported in the literature (5,11). In these cases, PS 80 was possibly stabilizing the 
antibody, predominantly by binding to its hydrophobic patches, and resulting complexes 
were unaffected by stirring, or a partial competitive adsorption was sufficient to inhibit 
aggregation (5). Out of every mechanical stress method utilized in this thesis, stirring was 
the most efficient in inducing nanoparticles for PS-free sample. This outcome could be 
explained by the fact that different mechanical stress methods were following dissimilar 
aggregates formation kinetics, which in the end resulted in formation of aggregates of 
different sizes.  
During the development of stirring stress method, we encountered various difficulties. Even 
though extensive cleaning of the micropaddles was carried out before each stirring 
experiment, particles stuck to the paddles were not removed, since on occasion stirred 
placebos exhibited increased particle concentration. Leached particles resembled silicone 
oil, indicating they could have originated from the silicon sheet, which was used to seal the 
stirring plate. Due to the minor amount of formed aggregates for proteinaceous samples 
containing MCPS 80 under stirring stress over 4h, stirring was prolonged to 24 and 36 hours. 
Nevertheless, this did not result in a greater particle formation in protein formulations 
containing MCPS 80. In addition, longer stirring durations led to sample evaporation. 5 mm 
and 7 mm silicone sheets were tested, and the latter was found to generate more particles 
under stirring stress for both PS-free and MCPS 80 containing samples. However, particle 
concentration obtained by using 7 mm silicone sheet, was different when measured by MFI 
or BMI. Counts of particles detected by BMI in comparison with MFI were distinctively 
lower, so this might indicate particles were either silicone oil droplets or air bubbles, that 
passed through the membrane during sample preparation. Acquired data on particles arising 
from stirring stress was overall very difficult to analyze, since substantial deviations were 
seen between individual columns and wells on the stirring plate for any stirring duration 
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silicone sheet or rotation speed used. Our goal was to compare particle concentrations with 
spiked PS 80, which was not possible for stirring, as it was too gentle and did not generate 
enough aggregates. Because of described complications, we decided micropaddle stirrer was 
not fit for PS 80 functionality evaluation and was for this reason not used for any follow-up 
experiments.  
5.5. Free-fall drop stress 
An unintentional drop of a vial or syringe with biopharmaceutic product is likely to happen 
somewhere between product transportation and administration. Those events are recognized 
as damaging in the literature (6,45,46), but very few studies have been performed to 
investigate the extent of protein damage upon exclusively free-fall stress. Therefore, 
generated data from the present study will enhance the understanding of this topic. Our 
findings for proteinaceous PS-free sample subjected to one or multiple free-falls were able 
to confirm damage to a biopharmaceutical product upon dropping. Additionally, we have 
demonstrated that with the increasing number of free-falls, aggregation was detected to a 
greater extent. Moreover, we managed to show the importance of the surfactant in preventing 
aggregation, since a very clear inhibitory effect of MCPS 80 was recognized. Not only it 
managed to prevent aggregates formation in micro-meter range but also no nanometer sized 
aggregates were detected. Similar to non-contact stirring stress this method was not rigorous 
enough to induce major particle formation in PS 80 containing samples, therefore it was not 
suitable for intended comparisons for this study.  
The root cause of protein aggregation under dropping stress is not fully understood yet, but 
there have been some propositions made in the literature. Randolph et al. suggested 
aggregation could be due to free radicals caused by rapid collapse of formed cavities (6). 
They also implied that because of the resemblance of aggregates formed by dropping with 
those arising from stirring or shaking stress, mechanical stress caused by cavitation bubbles 
could play a very important role in aggregates formation. Later Nakajima et al. proposed a 
more detailed explanation of aggregation due to cavitation (47). In the suggested pathway, 
protein molecules initially adsorb to the surface of the formed cavitation bubble and after 
the collapse, condensation of the protein monomers in the center of the former cavity and 
very high temperatures are deemed responsible for accelerating the nucleation reaction, 
which ultimately leads to aggregation.  
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PS 80, on the basis of implied mechanism by Nakajima et al., could possibly prevent 
aggregation by covering the cavitation bubble, and by doing so it would prevent the protein 
to adsorb to formed cavities (46,47). Moreover, when cavitation occurs in the proximity of 
protein molecules and causes unfolding, PS 80 could still manage to inhibit aggregation by 
contributing to decreased adsorption of perturbed protein to the solid-liquid interface (46). 
Our dropped vials visually looked different to undropped controls, as numerous 
bubbles/foam was seen immediately after one or multiple free-falls. But we were not able to 
detect a gelatinous protein film adsorbed to the vial wall, as seen in the study by Randolph 
et al. (6). Further, UV spectroscopy data at 280 nm showed no decrease in bulk protein 
concentration after stress treatment, therefore we concluded in our setting relatively little to 
no aggregates were attached to the vial wall after stress treatment. Randolph et al. (6) 
speculated that adhering of the protein aggregates could be due to the oxidative damage 
resulting from free radicals, high temperatures or mechanical stress caused by cavitation. 
Along with aggregation inspection, chemical changes after shock treatment to the protein 
could have been assessed in our study and may provide us with an answer to why formed 
aggregates were not attached to the vial wall, as reported in the abovementioned study (6). 
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6. Conclusions 
The developed pumping stress method proved to be a valuable method for characterizing 
PS 80 functionality, although improvements should be done to achieve better 
reproducibility. Our study has shown there is no significant difference in functionality of 
two different PS 80 quality grades. Further we revealed hydrolyzed PS 80 does not possess 
any stabilization properties. We also observed a concentration range where PS 80 is effective 
(0.004 %-0.1 % w/v). If concentration of PS 80 is too low, not only no stabilization of the 
protein occurs, but also a destabilizing effect is possible. It is common practice to add excess 
of PS to make sure a threshold PS concentration is present throughout the whole lifetime of 
a protein product (21). But with more PS material, we could risk presence of more PS 
byproducts and/or degradants. This is worrisome not only due to presence of insoluble 
particles e.g. FFAs, but also because of their negative impact on protein stability, proven in 
this thesis. Moreover, higher PS concentrations may even accelerate 
degradation/aggregation of the protein product (21,22,48). On the basis of our findings and 
existing literature, we suggest PS concentration in a formulation to be selected very carefully 
as either too low or too high concentrations are not favorable. 
It would be vital to understand what is causing aggregation under pumping stress method. 
Experiments with plunger not touching the liquid inside the syringes should be carried out 
to determine, if the scraping of the protein off the syringe wall is really the origin of 
aggregates formation. The same experiment should be executed by using capillary with ID 
0.25 mm to determine if very high shear is able to cause damage to the protein. Other 
reproducible mechanical stress methods should be developed to better assess functionality 
of different PS quality grades. In addition, stabilization properties of oxidized PS should be 
determined, as oxidation is the most common way of PS 80 degradation. It would be also 
reasonable to define which fraction in neat PS 80 material is responsible for its functionality. 
By doing so, unneeded fractions could be eliminated from intact PS material, which would 
make intact PS material less complex and easier to analyze and control. 
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